US20030167034A1 - Automatic fever abatement applications - Google Patents
Automatic fever abatement applications Download PDFInfo
- Publication number
- US20030167034A1 US20030167034A1 US10/188,778 US18877802A US2003167034A1 US 20030167034 A1 US20030167034 A1 US 20030167034A1 US 18877802 A US18877802 A US 18877802A US 2003167034 A1 US2003167034 A1 US 2003167034A1
- Authority
- US
- United States
- Prior art keywords
- fever
- patient
- controller
- treatment substance
- path
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
Definitions
- the present invention relates to a system that abates fever in hospital patients by administering medication, coolant, or other treatment substance.
- temperature regulation is one of the most important functions of the body.
- the human body seeks to maintain a core temperature of 37 degrees Celsius, and functions optimally when this temperature is achieved. Excessive temperatures cause various health problems, one of the most serious being brain damage. For patients with brain injury, fever can exacerbate neuronal outcomes.
- each of these techniques is manually activated by medical staff when they initially detect fever. Accordingly, some attention is required of medical staff in order to initially detect the onset of fever. This approach is therefore subject to some delay from the time medical staff recognize the start of fever until treatment is initiated. Importantly, the delay in applying treatment is a missed opportunity to prevent the fever in the first place. Moreover, during this delay, the fever may proceed into more serious stages. Thus, this delay can represent some health risk to the patient. As the science of medicine is interested in minimizing or reducing health risks wherever possible, the present Assignee realizes that known fever abatement approaches may not be completely satisfactory.
- the present invention concerns a machine-driven system to treat or even prevent fever in hospital patients by administering medication, coolant, or other treatment substance.
- One exemplary system includes a treatment substance administration path (“path”), a flow device, a source, one or more fever characteristic sensors, and a controller.
- the path may be an open-ended structure, such as a tube, or a closed-ended structure such as a catheter with a sealed, internal conduit.
- the treatment substance administration path is coupled to regions of the patient's body that will contain or absorb the treatment substance, as appropriate to the particular substance being used.
- the path is coupled to the flow device, which is itself attached to the source.
- the flow device comprises a pump, valve, or other suitable mechanism to regulate flow of the treatment substance from the source through the path.
- the source contains a treatment substance such as medication (in the case of an open-ended path) or a coolant (in the case of a closed-ended path).
- a treatment substance such as medication (in the case of an open-ended path) or a coolant (in the case of a closed-ended path).
- One or more fever characteristic sensors are attached to various sites on the patient.
- the system may also include a return vessel to receive treatment substance returning from the patient's body.
- the fever characteristic sensors repeatedly measure temperature, metabolic rate, and/or other bodily properties that are affected by fever, and provide representative machine-readable outputs.
- the controller repeatedly computes a supply strategy to regulate the patient's temperature according to pre-programmed specifications. Then, according to the computed strategy, the controller directs the flow device to deliver treatment substance to the path, and ultimately to the patient's body.
- the controller may activate other antipyretic means by (1) starting, adjusting, or redirecting a fan, (2) adjusting an air conditioning thermostat, (3) issuing visual or audible warning signals to hospital staff, etc.
- the invention may be implemented to provide a method to automatically treat or prevent fever in hospital patients by administering medication, coolant, or other antipyretic treatment substance.
- the invention may be implemented to provide an apparatus, such as fever abatement system, for automatically treating or preventing fever in hospital patients.
- the invention may be implemented to provide a signal-bearing medium tangibly embodying a program of machine-readable instructions executable by a digital data processing apparatus to perform operations to manage components of an automatic fever abatement system.
- Another embodiment concerns logic circuitry having multiple interconnected electrically conductive elements configured to perform operations to manage components of an automatic fever abatement system.
- the invention affords its users with a number of distinct advantages.
- the invention automatically initiates a procedure to cool the patient. Unlike the prior art, there is no delay before medical staff recognize the start of fever. In fact, actions may be taken before the body even exhibits any temperature rise. With the invention, rapid delivery of a therapeutic drug can begin within minutes from fever recognition.
- the invention utilizes machine control to minimize operator supervision, and thereby reduces operating costs and frees medical staff for other duties. Accordingly, the prompt recognition and treatment of fever no longer requires twenty-four hour, minute-by-minute attention from hospital staff and doctors.
- fever detection characteristics may be customized for each patient to ensure early and accurate fever detection.
- the invention also provides a number of other advantages and benefits, which should be apparent from the following description of the invention.
- FIG. 1A is a schematic diagram of a fever abatement system according to the invention.
- FIG. 1B is a diagram of a closed-end treatment substance administration path according to the invention.
- FIG. 1C is a diagram of an open-end treatment substance administration path according to the invention.
- FIG. 2 is a diagram of a digital data processing apparatus according to the invention.
- FIG. 3 shows an exemplary signal-bearing medium according to the invention.
- FIG. 4 is a flowchart of an operating sequence for automated fever abatement according to the invention.
- One aspect of the invention concerns a machine-driven system to treat or prevent fever in hospital patients by administering medication, coolant, or other antipyretic means.
- This system may be implemented in various ways, one example being shown by the hardware components and interconnections shown by the system 100 of FIG. 1.
- the system 100 includes a controller 104 , one or more fever characteristic sensors 106 , a flow device 110 , a treatment substance administration path 108 , and a source 112 .
- the system 100 is utilized to automatically treat or even prevent fever in the patient 102 .
- the system 100 includes one or more fever characteristic sensor(s) 106 .
- fever is defined as bodily temperature that is above normal due to pathogens or other stimuli.
- the system of this invention may be configured to detect fever; more advantageously from the standpoint of preventing fever, the invention may be configured to predictively detect the future onset of fever. Utilizing the foregoing definition of fever, the presence of fever is easily determined by detecting an elevated body temperature.
- the fever characteristic sensors 106 may include one or more temperature sensors, deployed in various regions of the body that accurately represent the temperature of the entire body, the body core, or a particular region.
- a single temperature sensor may be deployed at the esophagus, bladder, tympanic membrane, rectum, or another local site that is representative of the body's core temperature. With multiple temperature sensors, the sensors may be distributed at various sites, and the resulting measurements averaged to provide a more accurate representation of the patient's temperature.
- the fever characteristic sensors 106 may also include other sensors to detect the onset of fever. Since fever is preceded by increased metabolic rate, the sensors 106 may also include devices to detect increased oxygen consumption, increased carbon dioxide in exhaled air, decreased venous hemoglobin oxygen saturation, and the like. In the case of oxygen consumption or carbon dioxide measurement, the sensors 106 may comprise a gas analyzer coupled to automatic ventilation equipment or an open mask apparatus. In the case of venous hemoglobin oxygen measurement, relevant sensors 106 may comprise optical light reflectance and/or transmission devices, such as commercially available devices for detecting blood saturation.
- the treatment substance administration path 108 provides a means to administer a treatment substance to the patient.
- the path 108 may be open-end or closed-end. With an open-end path, the treatment substance takes a one-way trip into a region of the patient's body that is likely to absorb, distribute, or effectively process the treatment substance.
- the open-end treatment substance administration path for example, may be routed to the patient's stomach, veins, arteries, esophagus, or rectum.
- the open-end path is advantageous for treatment substances that comprise medication, such as acetaminophen, in which case an exemplary treatment substance administration path may comprise a device such as nasogastric tube.
- FIG. 1C shows an exemplary open-end path 140 .
- the path 140 comprises a conduit having a body 146 with an inlet 142 and an outlet 144 .
- the open-end treatment substance administration path 140 is deployed by inserting the outlet 144 into an artery, vein, stomach, rectum, skin, lungs or other suitable body access point.
- Other examples of open-end path include a nasogastric tube, open-end catheter, intravenous needle, syringe, suppository, perforated tube for “drip” irrigation, transdermal patch, aerosol or other inhalant, etc.
- FIG. 1B shows an exemplary closed-end path 120 , which is embodied by a cooling catheter.
- the catheter 120 includes a housing 122 having distal 128 and proximal 130 ends.
- the housing 122 contains a conduit 123 that runs from the catheter's proximal end 130 to the distal end 128 and back again.
- the conduit 123 has a supply opening 126 and a return opening 124 .
- the conduit 123 therefore provides a round-trip path internal to the catheter 120 , where this path is sealed from any contact with the patient's body.
- the closed-end path 120 is deployed by inserting the distal end 128 into a suitable blood vessel such as the inferior vena cava.
- a suitable blood vessel such as the inferior vena cava.
- the flow device 110 controls flow of the treatment substance from a source 112 to the patient to help prevent or abate the patient's fever.
- the flow device 110 may comprise a pump or other structure that actively causes the treatment substance to flow through the path from the source 112 , where the source comprises an intravenous bag, vial, jar, carton, box, or other storage facility.
- the treatment substance flows by gravity and the flow device 110 comprises a valve, on-off switch, or other mechanism to regulate treatment substance flowing from the source 112 .
- the source 112 may comprise any intravenous bag, vial, jar, carton, box, or other storage facility, whether compressible or not.
- the source 112 has a dynamic volume and the treatment substance flows by reduction of the source's volume.
- the source 112 may be a self-compressed vessel (e.g., distended elastic container), or a compressible vessel whose volume decreases under external force (e.g., syringe, hydraulic vessel, compressible intravenous bag, chamber with piston-driven lid, etc.).
- the flow device 110 comprises a solenoid or other suitable device to regulate the amount of flow through the path; in the case of an externally compressed source 112 , the flow device 110 comprises a compression mechanism such as a hydraulic pump, motor, piston, pinchers, screw-driven vise, etc.
- a compression mechanism such as a hydraulic pump, motor, piston, pinchers, screw-driven vise, etc.
- the flow device 110 regulates flow of the treatment substance directly into the patient's body.
- the flow device 110 regulates flow of the treatment substance into the supply opening (e.g., 126 , FIG. 1B), and also collects spent treatment substance from the catheter's return opening (e.g., 124 , FIGURE 1B).
- the flow device 110 deposits returned treatment substance into the return vessel 114 .
- the return vessel 114 may be omitted when an open-end path is used, or if the return vessel 114 leads to, or is combined with, the source 112 .
- equipment for cooling the treatment substance may be implemented at the source 112 , the flow device 110 , return vessel 114 , or other suitable location.
- the path 108 may be configured to incorporate one or more fever characteristic sensors 106 .
- a rectal temperature probe may be combined with a path designed for exposure or insertion of an antipyretic drug or suppository.
- controller 104 may be coupled to one or more additional controller-activated antipyretic apparatuses, whether related to the administration of treatment substance or not.
- additional controller-activated antipyretic apparatuses include inflatable cooling blankets, oscillating or fixed fans, air conditioning thermostats for room air or bath water, etc.
- the controller 104 receives measurements from the sensor(s) 106 , and serves to regulate operation of the flow device 110 according to predetermined specifications.
- the controller 104 comprises an electronic module such as logic circuitry, discrete circuit elements, or a digital data processing apparatus (computer) that executes a program of machine-readable instructions.
- the controller 104 When implemented in logic circuitry or a computer, the controller 104 analyzes the patient's temperature and/or other fever characteristic signals utilizing the controller's own programming, and provides the resultant output signal to regulate the flow device 110 . When implemented in discrete circuitry, the circuitry or the controller 104 processes the patient's fever characteristics with circuitry to provide a resultant output signal that regulates the flow device 110 .
- the controller 104 is a digital data processing apparatus.
- This apparatus may be embodied by various hardware components and interconnections, one example appearing in FIG. 2.
- the apparatus 200 includes a processor 202 , such as a microprocessor or other processing machine, coupled to a storage 204 .
- the storage 204 includes a fast-access storage 206 , as well as nonvolatile storage 208 .
- the fast-access storage 206 may comprise random access memory (RAM), and may be used to store the programming instructions executed by the processor 202 .
- the nonvolatile storage 208 may comprise, for example, one or more magnetic data storage disks such as a “hard drive”, a tape drive, or any other suitable storage device.
- the apparatus 200 also includes an input/output 210 , such as a line, bus, cable, electromagnetic link, or other means for the processor 202 to exchange data with other hardware external to the apparatus 200 .
- a different embodiment of the invention implements the controller 104 with logic circuitry instead of computer-executed instructions.
- this logic may be implemented by constructing an application-specific integrated circuit (ASIC) having thousands of tiny integrated transistors.
- ASIC application-specific integrated circuit
- Such an ASIC may be implemented using CMOS, TTL, VLSI, or another suitable construction.
- Other alternatives include a digital signal processing chip (DSP), discrete circuitry (such as resistors, capacitors, diodes, inductors, and transistors), field programmable gate array (FPGA), programmable logic array (PLA), and the like.
- DSP digital signal processing chip
- FPGA field programmable gate array
- PLA programmable logic array
- a different aspect of the invention concerns a process for automated fever abatement. As illustrated below, this process includes steps that are manually performed, such as preparing the patient for treatment. The process also includes automatic, machine-activated steps that treat or even prevent the patient's fever.
- the automated fever abatement process may be implemented, for example, by operating the controller 104 , as embodied by a digital data processing apparatus 200 , to execute a sequence of machine-readable instructions. These instructions may reside in various types of signal-bearing media.
- one aspect of the present invention concerns a programmed product, comprising signal-bearing media tangibly embodying a program of machine-readable instructions executable by a digital data processor to operate the system 100 to perform automated fever abatement.
- This signal-bearing media may comprise, for example, RAM (not shown) contained within the controller 104 , as represented by the fast-access storage 206 , for example.
- the instructions may be contained in another signal-bearing media, such as a magnetic data storage diskette 300 (FIG. 3), directly or indirectly accessible by the processor 202 .
- the instructions may be stored on a variety of machine-readable data storage media, such as direct access storage (e.g., a conventional “hard drive,” redundant array of inexpensive disks (RAID), or another direct access storage device (DASD)), magnetic tape, electronic read-only memory (e.g., ROM, EPROM, or EEPROM), optical storage (e.g., CD-ROM, WORM, DVD, digital optical tape), paper “punch” cards, or other suitable signal-bearing media including transmission media such as digital and analog and communication links and wireless.
- direct access storage e.g., a conventional “hard drive,” redundant array of inexpensive disks (RAID), or another direct access storage device (DASD)
- magnetic tape e.g., electronic read-only memory (e.g., ROM, EPROM, or EEPROM), optical storage (e.g., CD-ROM, WORM, DVD, digital optical tape), paper “punch” cards, or other suitable signal-bearing media including transmission media such as digital and analog and communication links and wireless
- the method of automated fever abatement may be implemented using logic circuitry, without using a processor to execute instructions.
- the logic circuitry is implemented in the controller 104 , and serves to perform an operational sequence according to this invention as described below.
- the logic circuitry may be implemented using many different types of circuitry, as discussed above.
- FIG. 4 shows a sequence 400 that illustrates one example of the method aspect of the present invention.
- medical staff prepare the patient for treatment (step 404 ).
- such preparation may involve bathing, shaving, dressing, and other activities.
- medical staff interconnect the components of the system 100 and deploy the path 108 to the appropriate bodily site(s) (step 406 ).
- the assembly steps are omitted.
- medical staff deploy the fever characteristic sensor(s) 106 at target regions of the patient's body.
- the sensors begin to measure the relevant physiological characteristics and provide representative machine-readable outputs.
- steps 404 , 406 , and 408 are performed manually. As described below, however, steps 409 , 410 , 412 , and 414 are performed by the controller 104 and serve to implement an automated method of fever abatement.
- the controller 104 collects input for use in deciding how to operate the flow device 110 and thereby regulate the patient's temperature.
- the input of step 409 includes input from the sensor(s) 106 , such as body temperature, metabolic rate, and other bodily characteristics affected by fever.
- the input may also include other information such as (1) whether the path 108 is closed-end or open-end, (2) if the path 108 is open-end, the strength of the medication that constitutes the treatment substance, (3) the volume output of the flow device 110 , (4) the patient's temperature history, (5) the history of treatment substance application with the current patient, (6) any post-delivery time delay required for treatment substance to take effect, and (7) other such factors.
- the controller computes a supply strategy in step 410 .
- the supply strategy specifies a volume, timing, and rate of treatment substance supply that is calculated to regulate the patient's temperature according to predetermined specifications. These predetermined specifications are pre-programmed into the controller 104 . As an example, the predetermined specifications may dictate keeping the patient's core temperature at or below 37.5 degrees Celsius, limiting any temperature excursions to a maximum time or temperature, etc.
- the supply strategy constitutes the manner of treatment substance delivery that will achieve the predetermined specifications.
- the controller 104 considers the input from step 409 and applies a predetermined analysis to this data.
- the predetermined analysis may be specified by one or more equations, lookup tables, or other machine-readable information available to the controller 104 by software programming, hardware configuration, etc.
- the path 108 is closed-end and the treatment substance comprise room temperature or cooled saline, and the predetermined specifications require keeping the patient's core temperature below 37.5 degrees Celsius.
- the controller's strategy is (1) operating the flow device 110 to circulate coolant if the patient's temperature reaches 37.5 degrees Celsius, and (2) ceasing operation of the flow device 110 whenever the patient's temperature is below 37.5 degrees Celsius.
- the path 108 is open-end and the treatment substance comprises one or more antipyretic drugs such as acetaminophen, aspirin, naproxen, ibuprofen, etc.
- the controller 104 may compute a strategy that activates the flow device 110 to administer a bolus of the treatment substance upon detecting fever or febral onset.
- Bolus may be especially desirable because fever tends to occur in spikes with rapid onset, and rapid initial delivery in a bolus may rapidly establish a meaningful blood concentration of the antipyretic treatment substance.
- an initial bolus of one drug may be administered, and if fever persists, a second larger bolus of the same drug or a bolus of a second antipyretic drug is administered.
- the treatment substance may be administered with an increasing rate if a preset body temperature is reached or if a predetermined rate of temperature increase is detected.
- the controller 104 directs the administration equipment 100 to implement this strategy in step 412 .
- the controller 104 directs the flow device 110 to begin delivering the treatment substance to the path 108 according to the computed supply strategy.
- the flow device 110 comprises a valve
- step 412 involves opening, closing, or adjusting constriction of the valve.
- the flow rate may be controlled by varying pump speed or repeatedly turning a constant-speed pump on and off.
- the controller 104 may record the time that treatment began for subsequent documentation by nurses, etc.
- step 414 the controller 104 determines whether it has received an “off” command.
- the “off” command may be received by keyboard entry, manual activation of a switch (not shown) coupled to the controller 104 , expiration of a pre-programmed treatment period, etc. If the “off” command has not been received, the sequence 400 returns to step 409 , whereupon the controller 104 receives further input from the sensors 106 , adjusts the supply strategy if necessary (step 410 ), and directs the components of the system 100 accordingly (step 412 ).
- step 414 receives the “off” command, the routine 400 ends in step 416 .
Abstract
A method for treating fever by establishing a closed loop pathway to flow a treatment substance through a patient's body without the substance entering the patient's bloodstream, by engaging a fever characteristic sensor with the patient, by receiving a signal from such sensor and using the controller to control temperature and/or flow of the treatment substance.
Description
- This application is a Continuation of U.S. patent application Ser. No. 09/396,200 entitled Automatic Fever Abatement System, filed on Sep. 15, 1999, the disclosures of which are incorporated herein by reference in their entirety.
- 1. Field of the Invention
- The present invention relates to a system that abates fever in hospital patients by administering medication, coolant, or other treatment substance.
- 2. Description of the Related Art
- In warm blooded creatures, temperature regulation is one of the most important functions of the body. The human body seeks to maintain a core temperature of 37 degrees Celsius, and functions optimally when this temperature is achieved. Excessive temperatures cause various health problems, one of the most serious being brain damage. For patients with brain injury, fever can exacerbate neuronal outcomes.
- To treat fever, a number of different techniques are known. For example, patients often receive medication such as acetaminophen (Tylenol) or acetylsalicylic acid (aspirin). In one extreme technique, physicians cool the patient's entire body by packing it in ice. In another technique, the patient is covered with a cooling blanket, such as an inflatable cushion that is filled with a coolant such as air or water. There are also other traditional approaches such a gastric lavage with ice water, infusing cold solution, etc.
- One newly developed approach treats fever by circulating a coolant through a catheter placed inside a patient's body. The catheter may be inserted into veins, arteries, cavities, or other internal regions of the body. The present assignee has pioneered a number of different cooling catheters and techniques in this area. Several different examples are shown in U.S. application Ser. No. 09/133,813, which was filed on Aug. 13, 1998 and is hereby incorporated into the present application by reference.
- Regardless of which technique is ultimately used to treat a patient's fever, each of these techniques is manually activated by medical staff when they initially detect fever. Accordingly, some attention is required of medical staff in order to initially detect the onset of fever. This approach is therefore subject to some delay from the time medical staff recognize the start of fever until treatment is initiated. Importantly, the delay in applying treatment is a missed opportunity to prevent the fever in the first place. Moreover, during this delay, the fever may proceed into more serious stages. Thus, this delay can represent some health risk to the patient. As the science of medicine is interested in minimizing or reducing health risks wherever possible, the present Assignee realizes that known fever abatement approaches may not be completely satisfactory.
- Broadly, the present invention concerns a machine-driven system to treat or even prevent fever in hospital patients by administering medication, coolant, or other treatment substance. One exemplary system includes a treatment substance administration path (“path”), a flow device, a source, one or more fever characteristic sensors, and a controller. The path may be an open-ended structure, such as a tube, or a closed-ended structure such as a catheter with a sealed, internal conduit. The treatment substance administration path is coupled to regions of the patient's body that will contain or absorb the treatment substance, as appropriate to the particular substance being used. The path is coupled to the flow device, which is itself attached to the source. The flow device comprises a pump, valve, or other suitable mechanism to regulate flow of the treatment substance from the source through the path. The source contains a treatment substance such as medication (in the case of an open-ended path) or a coolant (in the case of a closed-ended path). One or more fever characteristic sensors are attached to various sites on the patient. In the case of a closed-ended path, the system may also include a return vessel to receive treatment substance returning from the patient's body.
- The fever characteristic sensors repeatedly measure temperature, metabolic rate, and/or other bodily properties that are affected by fever, and provide representative machine-readable outputs. Concurrently, the controller repeatedly computes a supply strategy to regulate the patient's temperature according to pre-programmed specifications. Then, according to the computed strategy, the controller directs the flow device to deliver treatment substance to the path, and ultimately to the patient's body. In addition to administering coolant, medication, or other treatment substance to treat fever, the controller may activate other antipyretic means by (1) starting, adjusting, or redirecting a fan, (2) adjusting an air conditioning thermostat, (3) issuing visual or audible warning signals to hospital staff, etc.
- In one embodiment, the invention may be implemented to provide a method to automatically treat or prevent fever in hospital patients by administering medication, coolant, or other antipyretic treatment substance. In another embodiment, the invention may be implemented to provide an apparatus, such as fever abatement system, for automatically treating or preventing fever in hospital patients. In still another embodiment, the invention may be implemented to provide a signal-bearing medium tangibly embodying a program of machine-readable instructions executable by a digital data processing apparatus to perform operations to manage components of an automatic fever abatement system. Another embodiment concerns logic circuitry having multiple interconnected electrically conductive elements configured to perform operations to manage components of an automatic fever abatement system.
- The invention affords its users with a number of distinct advantages. In addition to quickly recognizing the presence or future onset of fever, the invention automatically initiates a procedure to cool the patient. Unlike the prior art, there is no delay before medical staff recognize the start of fever. In fact, actions may be taken before the body even exhibits any temperature rise. With the invention, rapid delivery of a therapeutic drug can begin within minutes from fever recognition. As another benefit, the invention utilizes machine control to minimize operator supervision, and thereby reduces operating costs and frees medical staff for other duties. Accordingly, the prompt recognition and treatment of fever no longer requires twenty-four hour, minute-by-minute attention from hospital staff and doctors. As still another advantage, fever detection characteristics may be customized for each patient to ensure early and accurate fever detection. The invention also provides a number of other advantages and benefits, which should be apparent from the following description of the invention.
- FIG. 1A is a schematic diagram of a fever abatement system according to the invention.
- FIG. 1B is a diagram of a closed-end treatment substance administration path according to the invention.
- FIG. 1C is a diagram of an open-end treatment substance administration path according to the invention.
- FIG. 2 is a diagram of a digital data processing apparatus according to the invention.
- FIG. 3 shows an exemplary signal-bearing medium according to the invention.
- FIG. 4 is a flowchart of an operating sequence for automated fever abatement according to the invention.
- The nature, objectives, and advantages of the invention will become more apparent to those skilled in the art after considering the following detailed description in connection with the accompanying drawings.
- Hardware Components & Interconnections
- Automatic Fever Abatement System
- Introduction
- One aspect of the invention concerns a machine-driven system to treat or prevent fever in hospital patients by administering medication, coolant, or other antipyretic means. This system may be implemented in various ways, one example being shown by the hardware components and interconnections shown by the
system 100 of FIG. 1. Thesystem 100 includes acontroller 104, one or more fevercharacteristic sensors 106, aflow device 110, a treatmentsubstance administration path 108, and asource 112. Thesystem 100 is utilized to automatically treat or even prevent fever in thepatient 102. - Fever Characteristic Sensor(s)
- As mentioned above, the
system 100 includes one or more fever characteristic sensor(s) 106. As used herein, “fever” is defined as bodily temperature that is above normal due to pathogens or other stimuli. The system of this invention may be configured to detect fever; more advantageously from the standpoint of preventing fever, the invention may be configured to predictively detect the future onset of fever. Utilizing the foregoing definition of fever, the presence of fever is easily determined by detecting an elevated body temperature. In this respect, the fevercharacteristic sensors 106 may include one or more temperature sensors, deployed in various regions of the body that accurately represent the temperature of the entire body, the body core, or a particular region. As an example, a single temperature sensor may be deployed at the esophagus, bladder, tympanic membrane, rectum, or another local site that is representative of the body's core temperature. With multiple temperature sensors, the sensors may be distributed at various sites, and the resulting measurements averaged to provide a more accurate representation of the patient's temperature. - Advantageously, the fever
characteristic sensors 106 may also include other sensors to detect the onset of fever. Since fever is preceded by increased metabolic rate, thesensors 106 may also include devices to detect increased oxygen consumption, increased carbon dioxide in exhaled air, decreased venous hemoglobin oxygen saturation, and the like. In the case of oxygen consumption or carbon dioxide measurement, thesensors 106 may comprise a gas analyzer coupled to automatic ventilation equipment or an open mask apparatus. In the case of venous hemoglobin oxygen measurement,relevant sensors 106 may comprise optical light reflectance and/or transmission devices, such as commercially available devices for detecting blood saturation. - Treatment Substance Administration Path
- The treatment substance administration path108 (“path”) provides a means to administer a treatment substance to the patient. The
path 108 may be open-end or closed-end. With an open-end path, the treatment substance takes a one-way trip into a region of the patient's body that is likely to absorb, distribute, or effectively process the treatment substance. The open-end treatment substance administration path, for example, may be routed to the patient's stomach, veins, arteries, esophagus, or rectum. The open-end path is advantageous for treatment substances that comprise medication, such as acetaminophen, in which case an exemplary treatment substance administration path may comprise a device such as nasogastric tube. FIG. 1C shows an exemplary open-end path 140. Thepath 140 comprises a conduit having abody 146 with aninlet 142 and anoutlet 144. The open-end treatmentsubstance administration path 140 is deployed by inserting theoutlet 144 into an artery, vein, stomach, rectum, skin, lungs or other suitable body access point. Other examples of open-end path include a nasogastric tube, open-end catheter, intravenous needle, syringe, suppository, perforated tube for “drip” irrigation, transdermal patch, aerosol or other inhalant, etc. - In contrast to the open-end path, treatment substance circulates within the closed-end path without actually contacting the patient's body. This is beneficial if the treatment substance comprises a coolant such as saline. FIG. 1B shows an exemplary closed-
end path 120, which is embodied by a cooling catheter. Thecatheter 120 includes ahousing 122 having distal 128 and proximal 130 ends. Thehousing 122 contains aconduit 123 that runs from the catheter'sproximal end 130 to thedistal end 128 and back again. Theconduit 123 has asupply opening 126 and areturn opening 124. Theconduit 123 therefore provides a round-trip path internal to thecatheter 120, where this path is sealed from any contact with the patient's body. The closed-end path 120 is deployed by inserting thedistal end 128 into a suitable blood vessel such as the inferior vena cava. A number of exemplary catheters and their use are described in U.S. application Ser. No. 09/321,515, which was filed on May 27, 1999 and is hereby incorporated by reference into the present application. - Flow Device, Source, Return Vessel
- The
flow device 110 controls flow of the treatment substance from asource 112 to the patient to help prevent or abate the patient's fever. In one embodiment, theflow device 110 may comprise a pump or other structure that actively causes the treatment substance to flow through the path from thesource 112, where the source comprises an intravenous bag, vial, jar, carton, box, or other storage facility. In another embodiment, the treatment substance flows by gravity and theflow device 110 comprises a valve, on-off switch, or other mechanism to regulate treatment substance flowing from thesource 112. Here, thesource 112 may comprise any intravenous bag, vial, jar, carton, box, or other storage facility, whether compressible or not. In still another embodiment, thesource 112 has a dynamic volume and the treatment substance flows by reduction of the source's volume. Namely, thesource 112 may be a self-compressed vessel (e.g., distended elastic container), or a compressible vessel whose volume decreases under external force (e.g., syringe, hydraulic vessel, compressible intravenous bag, chamber with piston-driven lid, etc.). In the case of a self-compressedsource 112, theflow device 110 comprises a solenoid or other suitable device to regulate the amount of flow through the path; in the case of an externallycompressed source 112, theflow device 110 comprises a compression mechanism such as a hydraulic pump, motor, piston, pinchers, screw-driven vise, etc. Ordinarily skilled artisans (having the benefit of this disclosure) will recognize a variety of other options to implement theflow device 110 andsource 112. - In the case of an open-end path, the
flow device 110 regulates flow of the treatment substance directly into the patient's body. In the case of a closed-end path, theflow device 110 regulates flow of the treatment substance into the supply opening (e.g., 126, FIG. 1B), and also collects spent treatment substance from the catheter's return opening (e.g., 124, FIGURE 1B). Theflow device 110 deposits returned treatment substance into thereturn vessel 114. Thereturn vessel 114 may be omitted when an open-end path is used, or if thereturn vessel 114 leads to, or is combined with, thesource 112. When a closed-end path is used, equipment for cooling the treatment substance may be implemented at thesource 112, theflow device 110, returnvessel 114, or other suitable location. If desired, thepath 108 may be configured to incorporate one or more fevercharacteristic sensors 106. For instance, a rectal temperature probe may be combined with a path designed for exposure or insertion of an antipyretic drug or suppository. - Other Antipyretic Apparatus(es)
- In addition to the foregoing components, the
controller 104 may be coupled to one or more additional controller-activated antipyretic apparatuses, whether related to the administration of treatment substance or not. Some examples include inflatable cooling blankets, oscillating or fixed fans, air conditioning thermostats for room air or bath water, etc. - Controller-Generally
- The
controller 104 receives measurements from the sensor(s) 106, and serves to regulate operation of theflow device 110 according to predetermined specifications. To implement this automatic control feature, thecontroller 104 comprises an electronic module such as logic circuitry, discrete circuit elements, or a digital data processing apparatus (computer) that executes a program of machine-readable instructions. - When implemented in logic circuitry or a computer, the
controller 104 analyzes the patient's temperature and/or other fever characteristic signals utilizing the controller's own programming, and provides the resultant output signal to regulate theflow device 110. When implemented in discrete circuitry, the circuitry or thecontroller 104 processes the patient's fever characteristics with circuitry to provide a resultant output signal that regulates theflow device 110. - Controller-Digital Data Processing Apparatus
- As mentioned above, one embodiment of the
controller 104 is a digital data processing apparatus. This apparatus may be embodied by various hardware components and interconnections, one example appearing in FIG. 2. Theapparatus 200 includes aprocessor 202, such as a microprocessor or other processing machine, coupled to astorage 204. In the present example, thestorage 204 includes a fast-access storage 206, as well asnonvolatile storage 208. The fast-access storage 206 may comprise random access memory (RAM), and may be used to store the programming instructions executed by theprocessor 202. Thenonvolatile storage 208 may comprise, for example, one or more magnetic data storage disks such as a “hard drive”, a tape drive, or any other suitable storage device. Theapparatus 200 also includes an input/output 210, such as a line, bus, cable, electromagnetic link, or other means for theprocessor 202 to exchange data with other hardware external to theapparatus 200. - Despite the specific foregoing description, ordinarily skilled artisans (having the benefit of this disclosure) will recognize that the apparatus discussed above maybe implemented in a machine of different construction, without departing from the scope of the invention. As a specific example, one of the
components storage 204 may be provided on-board theprocessor 202, or even provided externally to theapparatus 200. - Controller-Logic Circuitry
- In contrast to the digital data storage apparatus discussed previously, a different embodiment of the invention implements the
controller 104 with logic circuitry instead of computer-executed instructions. Depending upon the particular requirements of the application in the areas of speed, expense, tooling costs, and the like, this logic may be implemented by constructing an application-specific integrated circuit (ASIC) having thousands of tiny integrated transistors. Such an ASIC may be implemented using CMOS, TTL, VLSI, or another suitable construction. Other alternatives include a digital signal processing chip (DSP), discrete circuitry (such as resistors, capacitors, diodes, inductors, and transistors), field programmable gate array (FPGA), programmable logic array (PLA), and the like. - Operation
- In addition to the structure described above, a different aspect of the invention concerns a process for automated fever abatement. As illustrated below, this process includes steps that are manually performed, such as preparing the patient for treatment. The process also includes automatic, machine-activated steps that treat or even prevent the patient's fever.
- Signal-Bearing Medium
- In the context of FIGS.1-2, the automated fever abatement process may be implemented, for example, by operating the
controller 104, as embodied by a digitaldata processing apparatus 200, to execute a sequence of machine-readable instructions. These instructions may reside in various types of signal-bearing media. In this respect, one aspect of the present invention concerns a programmed product, comprising signal-bearing media tangibly embodying a program of machine-readable instructions executable by a digital data processor to operate thesystem 100 to perform automated fever abatement. - This signal-bearing media may comprise, for example, RAM (not shown) contained within the
controller 104, as represented by the fast-access storage 206, for example. Alternatively, the instructions may be contained in another signal-bearing media, such as a magnetic data storage diskette 300 (FIG. 3), directly or indirectly accessible by theprocessor 202. Whether contained in thediskette 300,storage 204, or elsewhere, the instructions may be stored on a variety of machine-readable data storage media, such as direct access storage (e.g., a conventional “hard drive,” redundant array of inexpensive disks (RAID), or another direct access storage device (DASD)), magnetic tape, electronic read-only memory (e.g., ROM, EPROM, or EEPROM), optical storage (e.g., CD-ROM, WORM, DVD, digital optical tape), paper “punch” cards, or other suitable signal-bearing media including transmission media such as digital and analog and communication links and wireless. In an illustrative embodiment of the invention, the machine-readable instructions may comprise software object code, compiled from a language such as “C,” etc. - Logic Circuitry
- In contrast to the signal-bearing medium discussed above, the method of automated fever abatement may be implemented using logic circuitry, without using a processor to execute instructions. In this embodiment, the logic circuitry is implemented in the
controller 104, and serves to perform an operational sequence according to this invention as described below. The logic circuitry may be implemented using many different types of circuitry, as discussed above. - Overall Sequence of Operation
- FIG. 4 shows a
sequence 400 that illustrates one example of the method aspect of the present invention. For ease of explanation, but without any intended limitation, the example of FIG. 4 is described in the context of FIGS. 1-2, as described above. After thesequence 400 is initiated instep 402, medical staff prepare the patient for treatment (step 404). As an example, such preparation may involve bathing, shaving, dressing, and other activities. Next, medical staff interconnect the components of thesystem 100 and deploy thepath 108 to the appropriate bodily site(s) (step 406). Alternatively, if thesystem 100 components are pre-assembled, the assembly steps are omitted. After step 406, medical staff deploy the fever characteristic sensor(s) 106 at target regions of the patient's body. Upon completion of step 406, the sensors begin to measure the relevant physiological characteristics and provide representative machine-readable outputs. - As illustrated, steps404,406, and 408 are performed manually. As described below, however, steps 409, 410, 412, and 414 are performed by the
controller 104 and serve to implement an automated method of fever abatement. In step 409, thecontroller 104 collects input for use in deciding how to operate theflow device 110 and thereby regulate the patient's temperature. Among other possible input, the input of step 409 includes input from the sensor(s) 106, such as body temperature, metabolic rate, and other bodily characteristics affected by fever. The input may also include other information such as (1) whether thepath 108 is closed-end or open-end, (2) if thepath 108 is open-end, the strength of the medication that constitutes the treatment substance, (3) the volume output of theflow device 110, (4) the patient's temperature history, (5) the history of treatment substance application with the current patient, (6) any post-delivery time delay required for treatment substance to take effect, and (7) other such factors. - After step409, the controller computes a supply strategy in
step 410. The supply strategy specifies a volume, timing, and rate of treatment substance supply that is calculated to regulate the patient's temperature according to predetermined specifications. These predetermined specifications are pre-programmed into thecontroller 104. As an example, the predetermined specifications may dictate keeping the patient's core temperature at or below 37.5 degrees Celsius, limiting any temperature excursions to a maximum time or temperature, etc. - Thus, the supply strategy constitutes the manner of treatment substance delivery that will achieve the predetermined specifications. To compute the supply strategy, the
controller 104 considers the input from step 409 and applies a predetermined analysis to this data. The predetermined analysis may be specified by one or more equations, lookup tables, or other machine-readable information available to thecontroller 104 by software programming, hardware configuration, etc. - To illustrate
step 410 in greater detail some examples are provided. In a first example, thepath 108 is closed-end and the treatment substance comprise room temperature or cooled saline, and the predetermined specifications require keeping the patient's core temperature below 37.5 degrees Celsius. Here, one example of the controller's strategy is (1) operating theflow device 110 to circulate coolant if the patient's temperature reaches 37.5 degrees Celsius, and (2) ceasing operation of theflow device 110 whenever the patient's temperature is below 37.5 degrees Celsius. - In a second example, the
path 108 is open-end and the treatment substance comprises one or more antipyretic drugs such as acetaminophen, aspirin, naproxen, ibuprofen, etc. In this example, thecontroller 104 may compute a strategy that activates theflow device 110 to administer a bolus of the treatment substance upon detecting fever or febral onset. Bolus may be especially desirable because fever tends to occur in spikes with rapid onset, and rapid initial delivery in a bolus may rapidly establish a meaningful blood concentration of the antipyretic treatment substance. - As an alternative strategy, an initial bolus of one drug may be administered, and if fever persists, a second larger bolus of the same drug or a bolus of a second antipyretic drug is administered. Furthermore, once fever is detected (or febral inset predicted), the treatment substance may be administered with an increasing rate if a preset body temperature is reached or if a predetermined rate of temperature increase is detected.
- After the supply strategy is computed in
step 410, thecontroller 104 directs theadministration equipment 100 to implement this strategy instep 412. Namely, thecontroller 104 directs theflow device 110 to begin delivering the treatment substance to thepath 108 according to the computed supply strategy. Where theflow device 110 comprises a valve,step 412 involves opening, closing, or adjusting constriction of the valve. Where theflow device 110 is a pump, the flow rate may be controlled by varying pump speed or repeatedly turning a constant-speed pump on and off. Also instep 412, thecontroller 104 may record the time that treatment began for subsequent documentation by nurses, etc. - In
step 414, thecontroller 104 determines whether it has received an “off” command. The “off” command may be received by keyboard entry, manual activation of a switch (not shown) coupled to thecontroller 104, expiration of a pre-programmed treatment period, etc. If the “off” command has not been received, thesequence 400 returns to step 409, whereupon thecontroller 104 receives further input from thesensors 106, adjusts the supply strategy if necessary (step 410), and directs the components of thesystem 100 accordingly (step 412). Whenstep 414 receives the “off” command, the routine 400 ends instep 416. - Other Embodiments
- While the foregoing disclosure shows a number of illustrative embodiments of the invention, it will be apparent to those skilled in the art that various changes and modifications can be made herein without departing from the scope of the invention as defined by the appended claims. Furthermore, although elements of the invention may be described or claimed in the singular, the plural is contemplated unless limitation to the singular is explicitly stated.
Claims (3)
1. A method for treating fever comprising:
establishing a pathway for fluid communication for a treatment substance to flow in a closed loop through a patient's body without entering the bloodstream;
engaging at least one fever characteristic sensor with the patient;
receiving signals from the sensor at a controller;
using the controller to control at least one of: temperature, and flow, of the treatment substance to counter fever in the patient.
2. The method of claim 1 , wherein the controller counters fever by alleviating fever once the sensor indicates that the patient is febrile.
3. The method of claim 1 , wherein the controller counters fever by prophylactically preventing a febrile episode.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/188,778 US20030167034A1 (en) | 1999-09-15 | 2002-07-03 | Automatic fever abatement applications |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/396,200 US6447474B1 (en) | 1999-09-15 | 1999-09-15 | Automatic fever abatement system |
US10/188,778 US20030167034A1 (en) | 1999-09-15 | 2002-07-03 | Automatic fever abatement applications |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/396,200 Continuation US6447474B1 (en) | 1999-09-15 | 1999-09-15 | Automatic fever abatement system |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030167034A1 true US20030167034A1 (en) | 2003-09-04 |
Family
ID=23566269
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/396,200 Expired - Lifetime US6447474B1 (en) | 1999-09-15 | 1999-09-15 | Automatic fever abatement system |
US10/188,778 Abandoned US20030167034A1 (en) | 1999-09-15 | 2002-07-03 | Automatic fever abatement applications |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/396,200 Expired - Lifetime US6447474B1 (en) | 1999-09-15 | 1999-09-15 | Automatic fever abatement system |
Country Status (3)
Country | Link |
---|---|
US (2) | US6447474B1 (en) |
AU (1) | AU7584700A (en) |
WO (1) | WO2001019447A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130222138A1 (en) * | 2011-08-24 | 2013-08-29 | Safetyminded Holdings, Inc. | Human Safety Indicator |
US11766180B1 (en) | 2020-12-07 | 2023-09-26 | Mark Newton | Identification of a true febrile state in humans through comparison of simultaneously measured core and peripheral temperatures |
EP4099965A4 (en) * | 2020-02-04 | 2024-02-21 | Zoll Circulation Inc | Determining a value indicative of a thermoregulatory activity of a patient using a temperature management system |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379378B1 (en) | 2000-03-03 | 2002-04-30 | Innercool Therapies, Inc. | Lumen design for catheter |
US6325818B1 (en) | 1999-10-07 | 2001-12-04 | Innercool Therapies, Inc. | Inflatable cooling apparatus for selective organ hypothermia |
US6585752B2 (en) | 1998-06-23 | 2003-07-01 | Innercool Therapies, Inc. | Fever regulation method and apparatus |
US6602276B2 (en) | 1998-03-31 | 2003-08-05 | Innercool Therapies, Inc. | Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation |
US6685732B2 (en) | 1998-03-31 | 2004-02-03 | Innercool Therapies, Inc. | Method and device for performing cooling- or cryo-therapies for, e.g., angioplasty with reduced restenosis or pulmonary vein cell necrosis to inhibit atrial fibrillation employing microporous balloon |
US8128595B2 (en) | 1998-04-21 | 2012-03-06 | Zoll Circulation, Inc. | Method for a central venous line catheter having a temperature control system |
US6338727B1 (en) | 1998-08-13 | 2002-01-15 | Alsius Corporation | Indwelling heat exchange catheter and method of using same |
US6554797B1 (en) | 1999-02-19 | 2003-04-29 | Alsius Corporation | Method and system for patient temperature management and central venous access |
US6585692B1 (en) | 1999-02-19 | 2003-07-01 | Alsius Corporation | Method and system for patient temperature management and central venous access |
US6447474B1 (en) * | 1999-09-15 | 2002-09-10 | Alsius Corporation | Automatic fever abatement system |
US6719723B2 (en) | 2000-12-06 | 2004-04-13 | Innercool Therapies, Inc. | Multipurpose catheter assembly |
US6450987B1 (en) | 2001-02-01 | 2002-09-17 | Innercool Therapies, Inc. | Collapsible guidewire lumen |
US6544282B1 (en) | 2001-02-21 | 2003-04-08 | Radiant Medical, Inc. | Inhibition of platelet activation, aggregation and/or adhesion by hypothermia |
US6723086B2 (en) * | 2001-05-07 | 2004-04-20 | Logiq Wireless Solutions, Inc. | Remote controlled transdermal medication delivery device |
US6679906B2 (en) * | 2001-07-13 | 2004-01-20 | Radiant Medical, Inc. | Catheter system with on-board temperature probe |
US20040199114A1 (en) * | 2003-04-01 | 2004-10-07 | Alsius Corporation | Intravascular heat exchange catheter with tissue preservative |
US20060190066A1 (en) * | 2005-02-23 | 2006-08-24 | Worthen William J | System and method for bringing hypothermia rapidly onboard |
US7425216B2 (en) | 2005-03-01 | 2008-09-16 | Alsius Corporation | System and method for treating cardiac arrest and myocardial infarction |
US7892269B2 (en) | 2005-04-18 | 2011-02-22 | Zoll Circulation, Inc. | External heat exchange pad for patient |
US7181927B2 (en) | 2005-07-01 | 2007-02-27 | Alsius Corporation | Primary heat exchanger for patient temperature control |
US7951182B2 (en) | 2005-07-14 | 2011-05-31 | Zoll Circulation, Inc. | System and method for leak detection in external cooling pad |
US20070093697A1 (en) | 2005-10-21 | 2007-04-26 | Theranova, Llc | Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature |
US20180311071A1 (en) | 2005-10-21 | 2018-11-01 | Daniel R. BURNETT | Method and apparatus for peritoneal oxygenation |
WO2008021306A2 (en) * | 2006-08-15 | 2008-02-21 | Bio-Innovative Operations, Inc. | Computer adjusted pressure wound care devices, systems & methods |
US7822485B2 (en) | 2006-09-25 | 2010-10-26 | Zoll Circulation, Inc. | Method and apparatus for spinal cooling |
US7867266B2 (en) | 2006-11-13 | 2011-01-11 | Zoll Circulation, Inc. | Temperature management system with assist mode for use with heart-lung machine |
US7892270B2 (en) | 2006-11-21 | 2011-02-22 | Zoll Circulation Inc. | Temperature management system and method for burn patients |
US8353893B2 (en) | 2007-03-07 | 2013-01-15 | Zoll Circulation, Inc. | System and method for rapidly cooling cardiac arrest patient |
CA2684807A1 (en) | 2007-04-05 | 2008-10-16 | Velomedix, Inc. | Automated therapy system and method |
US9737692B2 (en) | 2007-05-18 | 2017-08-22 | Zoll Circulation, Inc. | System and method for effecting non-standard fluid line connections |
US8439960B2 (en) | 2007-07-09 | 2013-05-14 | Velomedix, Inc. | Hypothermia devices and methods |
US9470584B2 (en) * | 2010-05-27 | 2016-10-18 | Exergen Corporation | Method and apparatus for accurate detection of fever |
US9622670B2 (en) | 2010-07-09 | 2017-04-18 | Potrero Medical, Inc. | Method and apparatus for pressure measurement |
AU2012286892B2 (en) | 2011-07-25 | 2016-04-21 | Neurosave, Inc. | Non-invasive systems, devices, and methods for selective brain cooling |
EP2932945A1 (en) * | 2014-04-17 | 2015-10-21 | seiratherm GmbH | Apparatus, system and method for controlling a temperature of a patient |
Citations (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US32983A (en) * | 1861-08-06 | Cast-ibon ordnance | ||
US33561A (en) * | 1861-10-22 | Improvement in valves and valve-motions for steam-engines | ||
US396200A (en) * | 1889-01-15 | Henry p | ||
US2058780A (en) * | 1931-03-28 | 1936-10-27 | Elliott Charles Robert | Thermo-therapeutical method and apparatus |
US2077453A (en) * | 1934-03-29 | 1937-04-20 | American Anode Inc | Therapeutical appliance |
US2308484A (en) * | 1939-01-16 | 1943-01-19 | Davol Rubber Co | Catheter |
US3125096A (en) * | 1964-03-17 | Compressor | ||
US3142157A (en) * | 1960-09-20 | 1964-07-28 | Council Scient Ind Res | Positive displacement pressure fluid pumps and motors |
US3238944A (en) * | 1962-10-08 | 1966-03-08 | Max L Hirschhorn | Temperature controlling device for living organs |
US3282267A (en) * | 1964-05-05 | 1966-11-01 | Eidus William | Thermoelectric hypothermia instrument |
US3327713A (en) * | 1964-06-18 | 1967-06-27 | Eidus William | Portable thermoelectric hypothermia device |
US3425419A (en) * | 1964-08-08 | 1969-02-04 | Angelo Actis Dato | Method of lowering and raising the temperature of the human body |
US3504674A (en) * | 1966-12-22 | 1970-04-07 | Emil S Swenson | Method and apparatus for performing hypothermia |
US3738372A (en) * | 1972-01-13 | 1973-06-12 | T Shioshvili | Apparatus for application of local hypothermy to the kidney |
US3776241A (en) * | 1971-08-13 | 1973-12-04 | Univ Iowa State Res Found Inc | System and method for controlling vascular responses |
US3897790A (en) * | 1971-08-13 | 1975-08-05 | Univ Iowa State Res Found Inc | Method for controlling vascular responses |
US4010795A (en) * | 1973-08-02 | 1977-03-08 | Gambro Ag | Cooling unit |
US4111209A (en) * | 1977-04-18 | 1978-09-05 | Datascope Corporation | Topical hypothermia apparatus and method for treating the human body and the like |
US4154245A (en) * | 1977-07-11 | 1979-05-15 | Daily Pat O | Apparatus for local hypothermia |
US4249923A (en) * | 1979-07-10 | 1981-02-10 | Walda Kim L | Cardioplegic fluid refrigeration and delivery system |
US4298006A (en) * | 1980-04-30 | 1981-11-03 | Research Against Cancer, Inc. | Systemic hyperthermia with improved temperature sensing apparatus and method |
US4416281A (en) * | 1981-03-05 | 1983-11-22 | Guardline Disposables Limited | Surgical cushion for cooling an organ |
US4416280A (en) * | 1980-04-07 | 1983-11-22 | Minnesota Mining And Manufacturing Company | Cardioplegia delivery system |
US4583969A (en) * | 1984-06-26 | 1986-04-22 | Mortensen J D | Apparatus and method for in vivo extrapulmonary blood gas exchange |
US4672962A (en) * | 1983-09-28 | 1987-06-16 | Cordis Corporation | Plaque softening method |
US4745922A (en) * | 1986-07-11 | 1988-05-24 | Taylor Kenneth G | Cervical heat transfer and immobilization device |
US4748979A (en) * | 1985-10-07 | 1988-06-07 | Cordis Corporation | Plaque resolving device |
US4750493A (en) * | 1986-02-28 | 1988-06-14 | Brader Eric W | Method of preventing brain damage during cardiac arrest, CPR or severe shock |
US4754752A (en) * | 1986-07-28 | 1988-07-05 | Robert Ginsburg | Vascular catheter |
US4759349A (en) * | 1986-02-24 | 1988-07-26 | Vitalmetrics, Inc. | Surgical instrument having a heat sink for irrigation, aspiration, and illumination |
US4791930A (en) * | 1982-10-25 | 1988-12-20 | Junkosha Co., Ltd. | Cooler for human tissue for use during hyperthermia treatment against cancer |
US4813210A (en) * | 1985-09-27 | 1989-03-21 | Nissho Corporation | Radiation-sterilized, packaged medical device |
US4823076A (en) * | 1986-03-17 | 1989-04-18 | Tektronix, Inc. | Method and apparatus for triggering |
US4844074A (en) * | 1986-04-11 | 1989-07-04 | Rolitron Muszaki-Fejleszto Kisszovetkezet | Method and apparatus for introducing a fluid into a human or animal organism as well as method and heating device for temperature control |
US4850958A (en) * | 1988-06-08 | 1989-07-25 | Cardiopulmonics, Inc. | Apparatus and method for extrapulmonary blood gas exchange |
US4860744A (en) * | 1987-11-02 | 1989-08-29 | Raj K. Anand | Thermoelectrically controlled heat medical catheter |
US4883455A (en) * | 1988-09-13 | 1989-11-28 | Minnesota Mining And Manufacturing Company | Cardioplegia administration set |
US4899741A (en) * | 1987-01-14 | 1990-02-13 | Hgm Medical Laser Systems, Inc. | Laser heated probe and control system |
US4920963A (en) * | 1986-02-28 | 1990-05-01 | Brader Eric W | Apparatus for preventing brain damage during cardiac arrest, CPR or severe shock |
US4941475A (en) * | 1988-08-30 | 1990-07-17 | Spectramed, Inc. | Thermodilution by heat exchange |
US4987896A (en) * | 1981-03-28 | 1991-01-29 | Yoshiro Nakamatsu | Apparatus for increasing the activity of the human brain |
US5019075A (en) * | 1984-10-24 | 1991-05-28 | The Beth Israel Hospital | Method and apparatus for angioplasty |
US5021045A (en) * | 1988-04-28 | 1991-06-04 | Research Medical, Inc. | Retrograde venous cardioplegia catheters and methods of use and manufacture |
US5041089A (en) * | 1987-12-11 | 1991-08-20 | Devices For Vascular Intervention, Inc. | Vascular dilation catheter construction |
US5066578A (en) * | 1989-12-21 | 1991-11-19 | The Regents Of The University Of California | Long-term preservation of organs for transplantation |
US5078713A (en) * | 1988-12-01 | 1992-01-07 | Spembly Medical Limited | Cryosurgical probe |
US5092841A (en) * | 1990-05-17 | 1992-03-03 | Wayne State University | Method for treating an arterial wall injured during angioplasty |
US5098376A (en) * | 1989-12-22 | 1992-03-24 | Cardiopulmonics, Inc. | Apparatus and methods for furling and introducing an extrapulmonary blood gas exchange device |
US5106360A (en) * | 1987-09-17 | 1992-04-21 | Olympus Optical Co., Ltd. | Thermotherapeutic apparatus |
US5139496A (en) * | 1990-12-20 | 1992-08-18 | Hed Aharon Z | Ultrasonic freeze ablation catheters and probes |
US5147385A (en) * | 1989-11-01 | 1992-09-15 | Schneider (Europe) A.G. | Stent and catheter for the introduction of the stent |
US5151100A (en) * | 1988-10-28 | 1992-09-29 | Boston Scientific Corporation | Heating catheters |
US5158534A (en) * | 1990-07-03 | 1992-10-27 | Cardiopulmonics, Inc. | Automated gas delivery system for blood gas exchange devices |
US5174285A (en) * | 1990-01-08 | 1992-12-29 | Lake Shore Medical Development Partners Ltd. | Localized heat transfer device |
US5182317A (en) * | 1988-06-08 | 1993-01-26 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
US5191883A (en) * | 1988-10-28 | 1993-03-09 | Prutech Research And Development Partnership Ii | Device for heating tissue in a patient's body |
US5196024A (en) * | 1990-07-03 | 1993-03-23 | Cedars-Sinai Medical Center | Balloon catheter with cutting edge |
US5211631A (en) * | 1991-07-24 | 1993-05-18 | Sheaff Charles M | Patient warming apparatus |
US5230862A (en) * | 1991-08-16 | 1993-07-27 | Cardiopulmonics, Inc. | Apparatus for extracorporeal blood oxygenation |
US5248312A (en) * | 1992-06-01 | 1993-09-28 | Sensor Electronics, Inc. | Liquid metal-filled balloon |
US5250070A (en) * | 1991-05-28 | 1993-10-05 | Parodi Juan C | Less traumatic angioplasty balloon for arterial dilatation |
US5257977A (en) * | 1990-03-22 | 1993-11-02 | Argomed Ltd. | Technique for localized thermal treatment of mammals |
US5260399A (en) * | 1992-06-08 | 1993-11-09 | General Electric Company | Regiospecific catalyst for the synthesis of epoxysiloxane monomers and polymers |
US5262451A (en) * | 1988-06-08 | 1993-11-16 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
US5269595A (en) * | 1992-10-19 | 1993-12-14 | Westinghouse Air Brake Company | Empty/load changeover valve for railway car |
US5281213A (en) * | 1992-04-16 | 1994-01-25 | Implemed, Inc. | Catheter for ice mapping and ablation |
US5338770A (en) * | 1988-06-08 | 1994-08-16 | Cardiopulmonics, Inc. | Gas permeable thrombo-resistant coatings and methods of manufacture |
US5342301A (en) * | 1992-08-13 | 1994-08-30 | Advanced Polymers Incorporated | Multi-lumen balloons and catheters made therewith |
US5342693A (en) * | 1988-06-08 | 1994-08-30 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coating and methods of manufacture |
US5354277A (en) * | 1992-09-04 | 1994-10-11 | Biocontrol Technology, Inc. | Specialized perfusion protocol for whole-body hyperthermia |
US5423807A (en) * | 1992-04-16 | 1995-06-13 | Implemed, Inc. | Cryogenic mapping and ablation catheter |
US5437673A (en) * | 1993-02-04 | 1995-08-01 | Cryomedical Sciences, Inc. | Closed circulation tissue warming apparatus and method of using the same in prostate surgery |
US5478309A (en) * | 1994-05-27 | 1995-12-26 | William P. Sweezer, Jr. | Catheter system and method for providing cardiopulmonary bypass pump support during heart surgery |
US5486204A (en) * | 1994-09-20 | 1996-01-23 | University Of Texas Health Science Center Houston | Method of treating a non-penetrating head wound with hypothermia |
US5486208A (en) * | 1993-02-10 | 1996-01-23 | Ginsburg; Robert | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification |
US5531776A (en) * | 1993-09-24 | 1996-07-02 | The Ohio State University | Non-invasive aortic impingement and core and cerebral temperature manipulation method |
US5545161A (en) * | 1992-12-01 | 1996-08-13 | Cardiac Pathways Corporation | Catheter for RF ablation having cooled electrode with electrically insulated sleeve |
US5562606A (en) * | 1992-07-08 | 1996-10-08 | Huybregts; Marinus A. J. M. | Bi-caval cannula |
US5609620A (en) * | 1995-06-06 | 1997-03-11 | Pat O. Daily | Cardiac cooling jacket |
US5624392A (en) * | 1990-05-11 | 1997-04-29 | Saab; Mark A. | Heat transfer catheters and methods of making and using same |
US5655548A (en) * | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
US5656420A (en) * | 1995-02-24 | 1997-08-12 | University Of Kentucky Research Foundation | Method for employing the delta opioid dadle to extend tissue survival time during ischemia |
US5693080A (en) * | 1993-03-19 | 1997-12-02 | Wallsten Medical S.A. | Apparatus for medical treatment |
US5702435A (en) * | 1993-01-25 | 1997-12-30 | State Of Israel Ministry Of Defense, Rafael-Armaments | Fast changing heating-cooling device and method |
US5716386A (en) * | 1994-06-27 | 1998-02-10 | The Ohio State University | Non-invasive aortic impingement and core and cerebral temperature manipulation |
US5730720A (en) * | 1995-08-18 | 1998-03-24 | Ip Scientific, Inc. | Perfusion hyperthermia treatment system and method |
US5733319A (en) * | 1996-04-25 | 1998-03-31 | Urologix, Inc. | Liquid coolant supply system |
US5735809A (en) * | 1996-12-05 | 1998-04-07 | Matria Healthcare, Inc. | Fiber assembly for in vivo plasma separation |
US5758505A (en) * | 1995-10-12 | 1998-06-02 | Cryogen, Inc. | Precooling system for joule-thomson probe |
US5759182A (en) * | 1993-11-09 | 1998-06-02 | Spembly Medical Limited | Cryosurgical probe with pre-cooling feature |
US5787715A (en) * | 1995-10-12 | 1998-08-04 | Cryogen, Inc. | Mixed gas refrigeration method |
US5837003A (en) * | 1993-02-10 | 1998-11-17 | Radiant Medical, Inc. | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification |
US5916200A (en) * | 1997-10-01 | 1999-06-29 | Walter Lorenz Surgical, Inc. | Apparatus and method for stabilization of a cranial shunt |
US6264679B1 (en) * | 1999-08-20 | 2001-07-24 | Radiant Medical, Inc. | Heat exchange catheter with discrete heat exchange elements |
US6447474B1 (en) * | 1999-09-15 | 2002-09-10 | Alsius Corporation | Automatic fever abatement system |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3142158A (en) | 1962-05-28 | 1964-07-28 | Podolsky Leon | Thermoelectric cooling device |
GB1438759A (en) | 1972-06-02 | 1976-06-09 | Spembly Ltd | Cryo-surgical apparatus |
USRE32983E (en) | 1983-07-05 | 1989-07-11 | E. I. Du Pont De Nemours And Company | Balloon and manufacture thereof |
USRE33561E (en) | 1983-07-05 | 1991-03-26 | E. I. Du Pont De Nemours And Company | Balloon and manufacture thereof |
US5147355A (en) | 1988-09-23 | 1992-09-15 | Brigham And Womens Hospital | Cryoablation catheter and method of performing cryoablation |
US5036462A (en) * | 1989-09-29 | 1991-07-30 | Healthtech Services Corp. | Interactive patient assistance and medication delivery systems responsive to the physical environment of the patient |
AU7773891A (en) | 1990-05-11 | 1991-12-10 | Mark A. Saab | High-strength, thin-walled single piece catheters |
TW279133B (en) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
US5261399A (en) | 1991-05-22 | 1993-11-16 | Klatz Ronald M | Brain cooling device and method for performing the same |
US5281215A (en) | 1992-04-16 | 1994-01-25 | Implemed, Inc. | Cryogenic catheter |
US5269758A (en) | 1992-04-29 | 1993-12-14 | Taheri Syde A | Intravascular catheter and method for treatment of hypothermia |
US5275595A (en) | 1992-07-06 | 1994-01-04 | Dobak Iii John D | Cryosurgical instrument |
US5324286A (en) | 1993-01-21 | 1994-06-28 | Arthur A. Fowle, Inc. | Entrained cryogenic droplet transfer method and cryosurgical instrument |
US5997501A (en) * | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
US5452582A (en) | 1994-07-06 | 1995-09-26 | Apd Cryogenics, Inc. | Cryo-probe |
US5916242A (en) * | 1996-11-04 | 1999-06-29 | Schwartz; George R. | Apparatus for rapid cooling of the brain and method of performing same |
US6095992A (en) * | 1998-04-06 | 2000-08-01 | Augustine Medical, Inc. | Wound treatment apparatus for normothermic treatment of wounds |
-
1999
- 1999-09-15 US US09/396,200 patent/US6447474B1/en not_active Expired - Lifetime
-
2000
- 2000-09-15 AU AU75847/00A patent/AU7584700A/en not_active Abandoned
- 2000-09-15 WO PCT/US2000/025388 patent/WO2001019447A1/en active Application Filing
-
2002
- 2002-07-03 US US10/188,778 patent/US20030167034A1/en not_active Abandoned
Patent Citations (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3125096A (en) * | 1964-03-17 | Compressor | ||
US33561A (en) * | 1861-10-22 | Improvement in valves and valve-motions for steam-engines | ||
US396200A (en) * | 1889-01-15 | Henry p | ||
US32983A (en) * | 1861-08-06 | Cast-ibon ordnance | ||
US2058780A (en) * | 1931-03-28 | 1936-10-27 | Elliott Charles Robert | Thermo-therapeutical method and apparatus |
US2077453A (en) * | 1934-03-29 | 1937-04-20 | American Anode Inc | Therapeutical appliance |
US2308484A (en) * | 1939-01-16 | 1943-01-19 | Davol Rubber Co | Catheter |
US3142157A (en) * | 1960-09-20 | 1964-07-28 | Council Scient Ind Res | Positive displacement pressure fluid pumps and motors |
US3238944A (en) * | 1962-10-08 | 1966-03-08 | Max L Hirschhorn | Temperature controlling device for living organs |
US3282267A (en) * | 1964-05-05 | 1966-11-01 | Eidus William | Thermoelectric hypothermia instrument |
US3327713A (en) * | 1964-06-18 | 1967-06-27 | Eidus William | Portable thermoelectric hypothermia device |
US3425419A (en) * | 1964-08-08 | 1969-02-04 | Angelo Actis Dato | Method of lowering and raising the temperature of the human body |
US3504674A (en) * | 1966-12-22 | 1970-04-07 | Emil S Swenson | Method and apparatus for performing hypothermia |
US3776241A (en) * | 1971-08-13 | 1973-12-04 | Univ Iowa State Res Found Inc | System and method for controlling vascular responses |
US3897790A (en) * | 1971-08-13 | 1975-08-05 | Univ Iowa State Res Found Inc | Method for controlling vascular responses |
US3738372A (en) * | 1972-01-13 | 1973-06-12 | T Shioshvili | Apparatus for application of local hypothermy to the kidney |
US4010795A (en) * | 1973-08-02 | 1977-03-08 | Gambro Ag | Cooling unit |
US4111209A (en) * | 1977-04-18 | 1978-09-05 | Datascope Corporation | Topical hypothermia apparatus and method for treating the human body and the like |
US4154245A (en) * | 1977-07-11 | 1979-05-15 | Daily Pat O | Apparatus for local hypothermia |
US4249923A (en) * | 1979-07-10 | 1981-02-10 | Walda Kim L | Cardioplegic fluid refrigeration and delivery system |
US4416280A (en) * | 1980-04-07 | 1983-11-22 | Minnesota Mining And Manufacturing Company | Cardioplegia delivery system |
US4298006A (en) * | 1980-04-30 | 1981-11-03 | Research Against Cancer, Inc. | Systemic hyperthermia with improved temperature sensing apparatus and method |
US4416281A (en) * | 1981-03-05 | 1983-11-22 | Guardline Disposables Limited | Surgical cushion for cooling an organ |
US4987896A (en) * | 1981-03-28 | 1991-01-29 | Yoshiro Nakamatsu | Apparatus for increasing the activity of the human brain |
US4791930A (en) * | 1982-10-25 | 1988-12-20 | Junkosha Co., Ltd. | Cooler for human tissue for use during hyperthermia treatment against cancer |
US4672962A (en) * | 1983-09-28 | 1987-06-16 | Cordis Corporation | Plaque softening method |
US4583969A (en) * | 1984-06-26 | 1986-04-22 | Mortensen J D | Apparatus and method for in vivo extrapulmonary blood gas exchange |
US5019075A (en) * | 1984-10-24 | 1991-05-28 | The Beth Israel Hospital | Method and apparatus for angioplasty |
US4813210A (en) * | 1985-09-27 | 1989-03-21 | Nissho Corporation | Radiation-sterilized, packaged medical device |
US4748979A (en) * | 1985-10-07 | 1988-06-07 | Cordis Corporation | Plaque resolving device |
US4759349A (en) * | 1986-02-24 | 1988-07-26 | Vitalmetrics, Inc. | Surgical instrument having a heat sink for irrigation, aspiration, and illumination |
US4750493A (en) * | 1986-02-28 | 1988-06-14 | Brader Eric W | Method of preventing brain damage during cardiac arrest, CPR or severe shock |
US4920963A (en) * | 1986-02-28 | 1990-05-01 | Brader Eric W | Apparatus for preventing brain damage during cardiac arrest, CPR or severe shock |
US4823076A (en) * | 1986-03-17 | 1989-04-18 | Tektronix, Inc. | Method and apparatus for triggering |
US4844074A (en) * | 1986-04-11 | 1989-07-04 | Rolitron Muszaki-Fejleszto Kisszovetkezet | Method and apparatus for introducing a fluid into a human or animal organism as well as method and heating device for temperature control |
US4745922A (en) * | 1986-07-11 | 1988-05-24 | Taylor Kenneth G | Cervical heat transfer and immobilization device |
US4754752A (en) * | 1986-07-28 | 1988-07-05 | Robert Ginsburg | Vascular catheter |
US4899741A (en) * | 1987-01-14 | 1990-02-13 | Hgm Medical Laser Systems, Inc. | Laser heated probe and control system |
US5106360A (en) * | 1987-09-17 | 1992-04-21 | Olympus Optical Co., Ltd. | Thermotherapeutic apparatus |
US4860744A (en) * | 1987-11-02 | 1989-08-29 | Raj K. Anand | Thermoelectrically controlled heat medical catheter |
US5041089A (en) * | 1987-12-11 | 1991-08-20 | Devices For Vascular Intervention, Inc. | Vascular dilation catheter construction |
US5021045A (en) * | 1988-04-28 | 1991-06-04 | Research Medical, Inc. | Retrograde venous cardioplegia catheters and methods of use and manufacture |
US5342693A (en) * | 1988-06-08 | 1994-08-30 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coating and methods of manufacture |
US5182317A (en) * | 1988-06-08 | 1993-01-26 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
US4850958A (en) * | 1988-06-08 | 1989-07-25 | Cardiopulmonics, Inc. | Apparatus and method for extrapulmonary blood gas exchange |
US5338770A (en) * | 1988-06-08 | 1994-08-16 | Cardiopulmonics, Inc. | Gas permeable thrombo-resistant coatings and methods of manufacture |
US5262451A (en) * | 1988-06-08 | 1993-11-16 | Cardiopulmonics, Inc. | Multifunctional thrombo-resistant coatings and methods of manufacture |
US4941475A (en) * | 1988-08-30 | 1990-07-17 | Spectramed, Inc. | Thermodilution by heat exchange |
US4883455A (en) * | 1988-09-13 | 1989-11-28 | Minnesota Mining And Manufacturing Company | Cardioplegia administration set |
US5151100A (en) * | 1988-10-28 | 1992-09-29 | Boston Scientific Corporation | Heating catheters |
US5191883A (en) * | 1988-10-28 | 1993-03-09 | Prutech Research And Development Partnership Ii | Device for heating tissue in a patient's body |
US5078713A (en) * | 1988-12-01 | 1992-01-07 | Spembly Medical Limited | Cryosurgical probe |
US5147385A (en) * | 1989-11-01 | 1992-09-15 | Schneider (Europe) A.G. | Stent and catheter for the introduction of the stent |
US5066578A (en) * | 1989-12-21 | 1991-11-19 | The Regents Of The University Of California | Long-term preservation of organs for transplantation |
US5098376A (en) * | 1989-12-22 | 1992-03-24 | Cardiopulmonics, Inc. | Apparatus and methods for furling and introducing an extrapulmonary blood gas exchange device |
US5174285A (en) * | 1990-01-08 | 1992-12-29 | Lake Shore Medical Development Partners Ltd. | Localized heat transfer device |
US5257977A (en) * | 1990-03-22 | 1993-11-02 | Argomed Ltd. | Technique for localized thermal treatment of mammals |
US5624392A (en) * | 1990-05-11 | 1997-04-29 | Saab; Mark A. | Heat transfer catheters and methods of making and using same |
US5092841A (en) * | 1990-05-17 | 1992-03-03 | Wayne State University | Method for treating an arterial wall injured during angioplasty |
US5158534A (en) * | 1990-07-03 | 1992-10-27 | Cardiopulmonics, Inc. | Automated gas delivery system for blood gas exchange devices |
US5196024A (en) * | 1990-07-03 | 1993-03-23 | Cedars-Sinai Medical Center | Balloon catheter with cutting edge |
US5139496A (en) * | 1990-12-20 | 1992-08-18 | Hed Aharon Z | Ultrasonic freeze ablation catheters and probes |
US5250070A (en) * | 1991-05-28 | 1993-10-05 | Parodi Juan C | Less traumatic angioplasty balloon for arterial dilatation |
US5279598A (en) * | 1991-07-24 | 1994-01-18 | Sheaff Charles M | Patient warming methods |
US5211631A (en) * | 1991-07-24 | 1993-05-18 | Sheaff Charles M | Patient warming apparatus |
US5230862A (en) * | 1991-08-16 | 1993-07-27 | Cardiopulmonics, Inc. | Apparatus for extracorporeal blood oxygenation |
US5281213A (en) * | 1992-04-16 | 1994-01-25 | Implemed, Inc. | Catheter for ice mapping and ablation |
US5423807A (en) * | 1992-04-16 | 1995-06-13 | Implemed, Inc. | Cryogenic mapping and ablation catheter |
US5248312A (en) * | 1992-06-01 | 1993-09-28 | Sensor Electronics, Inc. | Liquid metal-filled balloon |
US5260399A (en) * | 1992-06-08 | 1993-11-09 | General Electric Company | Regiospecific catalyst for the synthesis of epoxysiloxane monomers and polymers |
US5562606A (en) * | 1992-07-08 | 1996-10-08 | Huybregts; Marinus A. J. M. | Bi-caval cannula |
US5342301A (en) * | 1992-08-13 | 1994-08-30 | Advanced Polymers Incorporated | Multi-lumen balloons and catheters made therewith |
US5354277A (en) * | 1992-09-04 | 1994-10-11 | Biocontrol Technology, Inc. | Specialized perfusion protocol for whole-body hyperthermia |
US5269595A (en) * | 1992-10-19 | 1993-12-14 | Westinghouse Air Brake Company | Empty/load changeover valve for railway car |
US5545161A (en) * | 1992-12-01 | 1996-08-13 | Cardiac Pathways Corporation | Catheter for RF ablation having cooled electrode with electrically insulated sleeve |
US5702435A (en) * | 1993-01-25 | 1997-12-30 | State Of Israel Ministry Of Defense, Rafael-Armaments | Fast changing heating-cooling device and method |
US5437673A (en) * | 1993-02-04 | 1995-08-01 | Cryomedical Sciences, Inc. | Closed circulation tissue warming apparatus and method of using the same in prostate surgery |
US5486208A (en) * | 1993-02-10 | 1996-01-23 | Ginsburg; Robert | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification |
US5837003A (en) * | 1993-02-10 | 1998-11-17 | Radiant Medical, Inc. | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification |
US5693080A (en) * | 1993-03-19 | 1997-12-02 | Wallsten Medical S.A. | Apparatus for medical treatment |
US5531776A (en) * | 1993-09-24 | 1996-07-02 | The Ohio State University | Non-invasive aortic impingement and core and cerebral temperature manipulation method |
US5759182A (en) * | 1993-11-09 | 1998-06-02 | Spembly Medical Limited | Cryosurgical probe with pre-cooling feature |
US5478309A (en) * | 1994-05-27 | 1995-12-26 | William P. Sweezer, Jr. | Catheter system and method for providing cardiopulmonary bypass pump support during heart surgery |
US5716386A (en) * | 1994-06-27 | 1998-02-10 | The Ohio State University | Non-invasive aortic impingement and core and cerebral temperature manipulation |
US5486204A (en) * | 1994-09-20 | 1996-01-23 | University Of Texas Health Science Center Houston | Method of treating a non-penetrating head wound with hypothermia |
US5656420A (en) * | 1995-02-24 | 1997-08-12 | University Of Kentucky Research Foundation | Method for employing the delta opioid dadle to extend tissue survival time during ischemia |
US5609620A (en) * | 1995-06-06 | 1997-03-11 | Pat O. Daily | Cardiac cooling jacket |
US5730720A (en) * | 1995-08-18 | 1998-03-24 | Ip Scientific, Inc. | Perfusion hyperthermia treatment system and method |
US5758505A (en) * | 1995-10-12 | 1998-06-02 | Cryogen, Inc. | Precooling system for joule-thomson probe |
US5787715A (en) * | 1995-10-12 | 1998-08-04 | Cryogen, Inc. | Mixed gas refrigeration method |
US5758505C1 (en) * | 1995-10-12 | 2001-10-30 | Cryogen Inc | Precooling system for joule-thomson probe |
US5733319A (en) * | 1996-04-25 | 1998-03-31 | Urologix, Inc. | Liquid coolant supply system |
US5655548A (en) * | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
US5735809A (en) * | 1996-12-05 | 1998-04-07 | Matria Healthcare, Inc. | Fiber assembly for in vivo plasma separation |
US5916200A (en) * | 1997-10-01 | 1999-06-29 | Walter Lorenz Surgical, Inc. | Apparatus and method for stabilization of a cranial shunt |
US6264679B1 (en) * | 1999-08-20 | 2001-07-24 | Radiant Medical, Inc. | Heat exchange catheter with discrete heat exchange elements |
US6447474B1 (en) * | 1999-09-15 | 2002-09-10 | Alsius Corporation | Automatic fever abatement system |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130222138A1 (en) * | 2011-08-24 | 2013-08-29 | Safetyminded Holdings, Inc. | Human Safety Indicator |
US9183719B2 (en) | 2011-08-24 | 2015-11-10 | Safetyminded Holdings, Inc. | Human safety indicator |
US9501918B2 (en) * | 2011-08-24 | 2016-11-22 | Safetyminded Holdings, Inc. | Human safety indicator |
EP4099965A4 (en) * | 2020-02-04 | 2024-02-21 | Zoll Circulation Inc | Determining a value indicative of a thermoregulatory activity of a patient using a temperature management system |
US11766180B1 (en) | 2020-12-07 | 2023-09-26 | Mark Newton | Identification of a true febrile state in humans through comparison of simultaneously measured core and peripheral temperatures |
Also Published As
Publication number | Publication date |
---|---|
WO2001019447A1 (en) | 2001-03-22 |
US6447474B1 (en) | 2002-09-10 |
AU7584700A (en) | 2001-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6447474B1 (en) | Automatic fever abatement system | |
AU713134B2 (en) | Perfusion hyperthermia treatment system and method | |
JP5636020B2 (en) | catheter | |
US20020032430A1 (en) | Method and system for treating stroke using hypothermia | |
US8672884B2 (en) | Method and apparatus for peritoneal hypothermia and/or resuscitation | |
JP5410423B2 (en) | Hypothermia apparatus and method | |
US7241307B2 (en) | Method and apparatus for managing temperature in a patient | |
JP2008539034A (en) | Apparatus and method for heat exchange from improved body | |
US6623514B1 (en) | Method of cooling an organ | |
US11446177B2 (en) | Method and apparatus for peritoneal oxygenation | |
US9764071B2 (en) | Bursitis treatment device and method | |
WO2003054660A2 (en) | Modular thermal treatment systems with single-use disposable catheter assemblies and related methods | |
WO2001017471A1 (en) | Method and system for treating high intracranial pressure using hypothermia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALSIUS CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BALDING, DAVID P.;REEL/FRAME:013079/0137 Effective date: 20020624 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |